Oral Gepotidacin for The Treatment of Uncomplicated Urogenital Gonorrhea (EAGLE-1): A Phase 3 Randomized, Open-Label, Non-Inferiority, Multicenter Study
In this phase 3, open-label, sponsor-blinded, multicenter, non-inferiority study evaluating oral Gepotidacin (two 3000 mg doses administered 10–12 h apart) compared with 500 mg intramuscular ceftriaxone plus 1 g oral azithromycin for the treatment of gonorrhea, Gepotidacin demonstrated non-inferiority to ceftriaxone plus azithromycin for urogenital N gonorrhoeae, with no new safety concerns, offering a novel oral treatment option for uncomplicated urogenital gonorrhea. Full Access: The Lancet
A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
Fremanezumab (Ajovy) cut monthly migraine days in children and adolescents with episodic migraine, according to the SPACE trial. The phase III study showed a reduction in monthly migraine days in patients (mean age about 13 years). Full Access: Clinical Trials
Early-Life Ozone Exposure and Asthma and Wheeze in Children
In this multisite cohort study of 1188 children, higher mean O3 exposure between birth and age 2 years was associated both independently and within mixtures of fine particulate matter and nitrogen dioxide with higher odds of caregiver-reported asthma and wheeze at ages 4 to 6 years but not ages 8 to 9 years. These findings suggest that in areas of low ambient O3 pollution, early-life O3 exposure was associated with asthma and wheeze in children. Full Access: JAMA
Invasive Group A Streptococcal Infections in 10 US States
In this population-based study of 21 312 patients with invasive GAS infections from 2013 through 2022, overall incidence increased from 3.6 to 8.2 cases per 100 000 persons. Incidence was particularly high among those 65 years or older, American Indian or Alaska Native persons, residents of long-term care facilities, people experiencing homelessness, and people who inject drugs. Nonsusceptibility of isolates to macrolides and clindamycin increased substantially. Full Access: JAMA
